Page 39 - pesta2025_3
P. 39
Microbiological eradication
must become a clear therapeutic target in the fight against
fast-growing Gram-negative pathogen resistance 1–3
With current empiric standards being overcome and carbapenems
over-relied on, it’s clear we urgently need new options that prevent
pathogen recurrence 1–7
1. Kiem S & Schentag JJ. Infect Chemother 2013;45:283–291. 6. Mata C et al. Clin Microbiol Infect 2010;16(5):472–476.
2. Kadry N et al. Clin Infect Dis 2023; ciad010: doi: 7. World Health Organization. Antimicrobial resistance.
10.1093/cid/ciad010. Available at: https://www.who.int/news-room/fact-sheets/
3. Albin OR et al. Clin Infect Dis 2020;71:3033–3041. detail/antimicrobial-resistance. Accessed July 2024.
4. Boyd SE et al. Antimicrob Agents Chemother
2022;66:e0021622. This material is intended for Healthcare Professionals only.
5. Castanheira M et al. Open Forum Infect Dis 2019;6
(Suppl1):S23–S33.
Abcur AB – the Nordic division of ADVANZ PHARMA
Bergaliden 11, 252 23 Helsingborg. +46 42 135 770. advanzpharma.com
NO/CEFE/PM/0007 I 03/2025
